Prothena Co. PLC (NASDAQ:PRTA) Given Consensus Rating of “Hold” by Brokerages

Shares of Prothena Co. PLC (NASDAQ:PRTA) have been assigned an average recommendation of “Hold” from the seven brokerages that are currently covering the company, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $13.25.

A number of research firms have recently issued reports on PRTA. BidaskClub upgraded shares of Prothena from a “hold” rating to a “buy” rating in a report on Wednesday, December 4th. Zacks Investment Research downgraded shares of Prothena from a “buy” rating to a “hold” rating and set a $11.00 price objective on the stock. in a report on Wednesday, October 23rd. ValuEngine upgraded shares of Prothena from a “strong sell” rating to a “sell” rating in a report on Tuesday. Evercore ISI reiterated a “buy” rating and issued a $14.00 price objective on shares of Prothena in a report on Sunday, December 22nd. Finally, Nomura reiterated a “buy” rating and issued a $19.00 price objective on shares of Prothena in a report on Wednesday, January 1st.

Large investors have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. grew its stake in shares of Prothena by 7.0% in the second quarter. Charles Schwab Investment Management Inc. now owns 234,340 shares of the biotechnology company’s stock valued at $2,477,000 after buying an additional 15,301 shares in the last quarter. Tang Capital Management LLC grew its stake in shares of Prothena by 30.9% in the third quarter. Tang Capital Management LLC now owns 423,823 shares of the biotechnology company’s stock valued at $3,323,000 after buying an additional 100,000 shares in the last quarter. Endurant Capital Management LP bought a new position in shares of Prothena in the third quarter valued at $677,000. Millennium Management LLC grew its stake in shares of Prothena by 376.2% in the third quarter. Millennium Management LLC now owns 1,228,476 shares of the biotechnology company’s stock valued at $9,631,000 after buying an additional 970,503 shares in the last quarter. Finally, California Public Employees Retirement System grew its stake in shares of Prothena by 17.6% in the third quarter. California Public Employees Retirement System now owns 62,340 shares of the biotechnology company’s stock valued at $489,000 after buying an additional 9,349 shares in the last quarter. 93.97% of the stock is owned by institutional investors and hedge funds.

PRTA stock traded up $0.32 during mid-day trading on Thursday, hitting $15.55. 8,136 shares of the company were exchanged, compared to its average volume of 271,144. The company has a debt-to-equity ratio of 0.07, a quick ratio of 12.88 and a current ratio of 12.88. Prothena has a 1-year low of $6.71 and a 1-year high of $17.63. The firm has a market cap of $619.25 million, a P/E ratio of -4.29 and a beta of 2.34. The firm’s 50 day simple moving average is $14.28 and its 200 day simple moving average is $10.28.

Prothena (NASDAQ:PRTA) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.54) by $0.05. Prothena had a negative net margin of 10,450.00% and a negative return on equity of 26.02%. The company had revenue of $0.21 million for the quarter, compared to the consensus estimate of $0.15 million. On average, equities research analysts predict that Prothena will post -2 EPS for the current fiscal year.

Prothena Company Profile

Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis.

Featured Story: How can investors find ex-dividend dates?

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply